Growth Metrics

Incyte (INCY) Gross Margin (2010 - 2026)

Incyte posted quarterly Gross Margin of 91.79% for Q1 2026, down 126.0% year-on-year from 353.03% in Q1 2025, and little changed on a QoQ basis from 91.96% in Q4 2025.

Incyte (INCY) has 17 years of Gross Margin data on file, last reported at 91.79% in Q1 2026.

  • For the quarter ending Q1 2026, Gross Margin fell 126.0% year-over-year to 91.79%; the trailing twelve-month figure through Mar 2026 stood at 92.47% (down 18.0% YoY), and the FY2025 full-year result was 92.76%, up 12.0% from the prior year.
  • Gross Margin for Q1 2026 stood at 91.79%, roughly flat from 91.96% in the prior quarter.
  • Across five years, Gross Margin topped out at 94.44% in Q2 2022 and bottomed at 91.79% in Q1 2026.
  • The 5-year median for Gross Margin is 93.05% (2025), against an average of 93.04%.
  • The widest annual swing landed in 2022, when Gross Margin slumped 173 bps; it then soared 86 bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 93.62% in 2022, then fell by 1 bps to 93.12% in 2023, then decreased by 1 bps to 92.49% in 2024, then dropped by 1 bps to 91.96% in 2025, then decreased by 0 bps to 91.79% in 2026.
  • The last three Gross Margin figures came in at 91.79% (Q1 2026), 91.96% (Q4 2025), and 92.75% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Margin (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 79.04%
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 86.85%
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 91.79%
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 82.22%
10 Incyte 19.28 Bn 15.27 Bn 1.17 Bn 91.79%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 91.79%
Dec 31, 2025 91.96%
Sep 30, 2025 92.75%
Jun 30, 2025 93.52%
Mar 31, 2025 93.05%
Dec 31, 2024 92.49%
Sep 30, 2024 92.44%
Jun 30, 2024 92.66%
Mar 31, 2024 93.08%
Dec 31, 2023 93.12%
Sep 30, 2023 93.46%
Jun 30, 2023 92.84%
Mar 31, 2023 92.97%
Dec 31, 2022 93.62%
Sep 30, 2022 93.37%
Jun 30, 2022 94.44%
Mar 31, 2022 94.19%
Dec 31, 2021 94.92%
Sep 30, 2021 95.10%
Jun 30, 2021 94.61%
Mar 31, 2021 95.17%
Dec 31, 2020 95.40%
Sep 30, 2020 94.47%
Jun 30, 2020 95.15%
Mar 31, 2020 95.19%
Dec 31, 2019 94.44%
Sep 30, 2019 94.55%
Jun 30, 2019 94.45%
Mar 31, 2019 95.46%
Dec 31, 2018 95.01%
Sep 30, 2018 94.49%
Jun 30, 2018 95.23%
Mar 31, 2018 95.26%
Dec 31, 2017 94.97%
Sep 30, 2017 94.22%
Jun 30, 2017 93.79%
Mar 31, 2017 96.14%
Dec 31, 2016 93.99%
Sep 30, 2016 92.50%
Jun 30, 2016 94.98%
Mar 31, 2016 97.72%
Dec 31, 2015 96.02%
Sep 30, 2015 95.71%
Jun 30, 2015 96.16%
Mar 31, 2015 98.13%
Dec 31, 2014 98.04%
Sep 30, 2014 99.89%
Jun 30, 2014 99.81%
Mar 31, 2014 99.81%
Dec 31, 2013 99.83%
Sep 30, 2013 99.82%
Jun 30, 2013 99.85%
Mar 31, 2013 99.79%
Dec 31, 2012 99.91%
Sep 30, 2012 99.95%
Jun 30, 2012 99.98%
Mar 31, 2012 99.97%
Dec 31, 2011 100.00%
Sep 30, 2011 100.00%
Jun 30, 2011 99.88%
Mar 31, 2011 97.84%
Dec 31, 2010 100.02%
Sep 30, 2010 99.18%
Jun 30, 2010 99.71%
Mar 31, 2010 99.33%